Key market metrics for LINCOLN Pharmaceuticals (LINCOPH) listed on NSE. For pharmaceuticals sector companies, these metrics provide a snapshot of LINCOLN Pharmaceuticals's market valuation and enterprise value, essential for comparing against intrinsic value estimates.
We analyze LINCOLN Pharmaceuticals using multiple valuation models appropriate for PHARMACEUTICALS companies. For PHARMACEUTICALS companies, we use P/E Ratio Analysis, Discounted Cash Flow (DCF), and EPS Growth Valuation to determine fair value estimates for LINCOLN Pharmaceuticals stock.
10-year Price-to-Earnings ratio trend
Current P/E Ratio
14.35
Jun 03, 2026
5-Year Median P/E
12.14
5-Year Historical Median
Difference
2.21
18.2%
Analysis: LINCOLN Pharmaceuticals's current P/E ratio is 18.2% above its 5-year median, suggesting the stock may be overvalued relative to its historical earnings performance.
The P/E ratio measures how much investors pay for each rupee of earnings (Share Price / EPS). A higher PE suggests the market expects strong future growth, while a lower PE may indicate undervaluation or slower growth prospects. Compare LINCOLN Pharmaceuticals's current PE against its historical median and PHARMACEUTICALS peers to gauge whether the stock is trading at a premium or discount relative to its earnings.
Go beyond charts — get fair value estimates from multiple valuation models and detailed assessment breakdowns.
Just ₹833/month
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: FY 2025